Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study.
Saved in:
| Title: | Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study. |
|---|---|
| Authors: | Wan X; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China., Liu D; Department of Donation Intensive Care Unit, The First Hospital of Jilin University, Changchun, Jilin, China., Wang H; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China., Guo W; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China., Wang X; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China., Zhao Y; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China., Bai O; Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Jun 18; Vol. 17, pp. 1857350. Date of Electronic Publication: 2026 Jun 18 (Print Publication: 2026). |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1857350 |
